CXCR3 ligands in disease and therapy

Tumorigenesis and the angiogenic switch

Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559

The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis

Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222

Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3

Cole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2009 · Cited by 870

Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases

Antonelli, A., Ferrari, S. M., Giuggioli, D., Ferrannini, E., Ferri, C., & Fallahi, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.010 · Cited by 595

Neuroinflammatory processes in Alzheimer’s disease

Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433

Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease

Galimberti, D., Schoonenboom, N., Scheltens, P., Fenoglio, C., Bouwman, F., Venturelli, E., Guidi, I., Blankenstein, M. A., Bresolin, N., & Scarpini, E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.538 · Cited by 289

Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer’s disease

Xia, M. Q., Bacskai, B. J., Knowles, R. B., Qin, S. X., & Hyman, B. T. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00285-x · Cited by 269

A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4.

Gupta, S. K., Hassel, T., & Singh, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7799 · Cited by 141

High CXCL10 Expression in Rejected Kidneys and Predictive Role of Pretransplant Serum CXCL10 for Acute Rejection And Chronic Allograft Nephropathy

Lazzeri, E., Rotondi, M., Mazzinghi, B., Lasagni, L., Buonamano, A., Rosati, A., Pradella, F., Fossombroni, V., La Villa, G., Gacci, M., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000160759.85080.2e · Cited by 96

Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer’s Disease Patients from Healthy Subjects

Hochstrasser, T., Marksteiner, J., Defrancesco, M., Deisenhammer, E. A., Kemmler, G., & Humpel, C. (2011) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000330468 · Cited by 31

SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms

Wang, Y., Mohseni, M., Grauel, A., Diez, J. E., Guan, W., Liang, S., Choi, J. E., Pu, M., Chen, D., Laszewski, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-80999-x · Cited by 73

Biglycan, a novel trigger of Th1 and Th17 cell recruitment into the kidney

Nastase, M. V., Zeng-Brouwers, J., Beckmann, J., Tredup, C., Christen, U., Radeke, H. H., Wygrecka, M., & Schaefer, L. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.002 · Cited by 60

The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression

Yin, X., Wang, Z., Wu, T., Ma, M., Zhang, Z., Chu, Z., Hu, Q., Ding, H., Han, X., Xu, J., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02172-3 · Cited by 54